HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited is poised to present a wealth of clinical data at two major upcoming conferences, the ESMO Congress and the World Conference on Lung Cancer in 2024. Key highlights include promising results from the FLOWERS study for treating advanced non-small cell lung cancer with a combination of osimertinib and savolitinib showing improved efficacy over monotherapy. Additionally, the company will showcase further analyses on treatments for various cancers, including metastatic colorectal and gastric cancers.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
